Long-term treatment with beta-blockers after myocardial infarction

162 patients discharged from hospital after mycardial infarction were randomly allocated to two groups, one received alprenolol 400 mg daily and the other served as the control. The period of follow-up was two years and all other treatment given was standardized. The two groups did not differ with r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of clinical pharmacology 1976-06, Vol.10 (2), p.77
Hauptverfasser: Ahlmark, G, Saetre, H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 77
container_title European journal of clinical pharmacology
container_volume 10
creator Ahlmark, G
Saetre, H
description 162 patients discharged from hospital after mycardial infarction were randomly allocated to two groups, one received alprenolol 400 mg daily and the other served as the control. The period of follow-up was two years and all other treatment given was standardized. The two groups did not differ with respect to risk factors for myocardial infarction, the course of the acute infarct or treatment during follow-up. After two years one patient in the group treated with alprenolol had died suddenly as compared to nine in the control group. During the same period four fresh infarcts had occurred in the alprenolol group compared to 15 in the control group. Both these differences were statistically significant. Only four patients were obliged to discontinue beta-blocker treatment because of suspected side-effects. Long-term post-infarction treatment with beta-blockers appears to be an effective form of secondary therapy without serious side-effects.
doi_str_mv 10.1007/BF00609463
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_134897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>134897</sourcerecordid><originalsourceid>FETCH-LOGICAL-p174t-cea9eac6ae32a6dbd8f567208500b9180801fe1600c6ae3cc3909d6f04aac7763</originalsourceid><addsrcrecordid>eNotj7lOAzEUAF1whUBDTeEfMDzHuz5KEhFAWokG6ujZ-wyGveQ1Qvl7EKGaZjTSMHYl4UYCmNv1FkCDq7Q6YgsAJYV2Bs7Y-Tx_AMjagTplJ1JV1pkFWzfj8CYK5Z6XTFh6Ggr_TuWdeyoofDeGT8ozx_jr8H4_Bsxtwo6nIWIOJY3DBTuO2M10-c8le93ev2weRfP88LS5a8QkTVVEIHSEQSOpFerWtzbW2qzA1gDeSQsWZCSpAf6cEJQD1-oIFWIwRqsluz50py_fU7ubcuox73eHFfUDMaBIsQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-term treatment with beta-blockers after myocardial infarction</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Ahlmark, G ; Saetre, H</creator><creatorcontrib>Ahlmark, G ; Saetre, H</creatorcontrib><description>162 patients discharged from hospital after mycardial infarction were randomly allocated to two groups, one received alprenolol 400 mg daily and the other served as the control. The period of follow-up was two years and all other treatment given was standardized. The two groups did not differ with respect to risk factors for myocardial infarction, the course of the acute infarct or treatment during follow-up. After two years one patient in the group treated with alprenolol had died suddenly as compared to nine in the control group. During the same period four fresh infarcts had occurred in the alprenolol group compared to 15 in the control group. Both these differences were statistically significant. Only four patients were obliged to discontinue beta-blocker treatment because of suspected side-effects. Long-term post-infarction treatment with beta-blockers appears to be an effective form of secondary therapy without serious side-effects.</description><identifier>ISSN: 0031-6970</identifier><identifier>DOI: 10.1007/BF00609463</identifier><identifier>PMID: 134897</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Alprenolol - administration &amp; dosage ; Alprenolol - adverse effects ; Alprenolol - therapeutic use ; Angina Pectoris - epidemiology ; Arrhythmias, Cardiac - epidemiology ; Blood Pressure ; Cardiomegaly ; Clinical Trials as Topic ; Digitalis Glycosides - therapeutic use ; Disability Evaluation ; Female ; Follow-Up Studies ; Heart Rate ; Humans ; Hyperlipidemias - epidemiology ; Male ; Middle Aged ; Myocardial Infarction - drug therapy ; Placebos ; Recurrence ; Risk</subject><ispartof>European journal of clinical pharmacology, 1976-06, Vol.10 (2), p.77</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/134897$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahlmark, G</creatorcontrib><creatorcontrib>Saetre, H</creatorcontrib><title>Long-term treatment with beta-blockers after myocardial infarction</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>162 patients discharged from hospital after mycardial infarction were randomly allocated to two groups, one received alprenolol 400 mg daily and the other served as the control. The period of follow-up was two years and all other treatment given was standardized. The two groups did not differ with respect to risk factors for myocardial infarction, the course of the acute infarct or treatment during follow-up. After two years one patient in the group treated with alprenolol had died suddenly as compared to nine in the control group. During the same period four fresh infarcts had occurred in the alprenolol group compared to 15 in the control group. Both these differences were statistically significant. Only four patients were obliged to discontinue beta-blocker treatment because of suspected side-effects. Long-term post-infarction treatment with beta-blockers appears to be an effective form of secondary therapy without serious side-effects.</description><subject>Adult</subject><subject>Aged</subject><subject>Alprenolol - administration &amp; dosage</subject><subject>Alprenolol - adverse effects</subject><subject>Alprenolol - therapeutic use</subject><subject>Angina Pectoris - epidemiology</subject><subject>Arrhythmias, Cardiac - epidemiology</subject><subject>Blood Pressure</subject><subject>Cardiomegaly</subject><subject>Clinical Trials as Topic</subject><subject>Digitalis Glycosides - therapeutic use</subject><subject>Disability Evaluation</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart Rate</subject><subject>Humans</subject><subject>Hyperlipidemias - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Placebos</subject><subject>Recurrence</subject><subject>Risk</subject><issn>0031-6970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1976</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotj7lOAzEUAF1whUBDTeEfMDzHuz5KEhFAWokG6ujZ-wyGveQ1Qvl7EKGaZjTSMHYl4UYCmNv1FkCDq7Q6YgsAJYV2Bs7Y-Tx_AMjagTplJ1JV1pkFWzfj8CYK5Z6XTFh6Ggr_TuWdeyoofDeGT8ozx_jr8H4_Bsxtwo6nIWIOJY3DBTuO2M10-c8le93ev2weRfP88LS5a8QkTVVEIHSEQSOpFerWtzbW2qzA1gDeSQsWZCSpAf6cEJQD1-oIFWIwRqsluz50py_fU7ubcuox73eHFfUDMaBIsQ</recordid><startdate>19760615</startdate><enddate>19760615</enddate><creator>Ahlmark, G</creator><creator>Saetre, H</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19760615</creationdate><title>Long-term treatment with beta-blockers after myocardial infarction</title><author>Ahlmark, G ; Saetre, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p174t-cea9eac6ae32a6dbd8f567208500b9180801fe1600c6ae3cc3909d6f04aac7763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1976</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alprenolol - administration &amp; dosage</topic><topic>Alprenolol - adverse effects</topic><topic>Alprenolol - therapeutic use</topic><topic>Angina Pectoris - epidemiology</topic><topic>Arrhythmias, Cardiac - epidemiology</topic><topic>Blood Pressure</topic><topic>Cardiomegaly</topic><topic>Clinical Trials as Topic</topic><topic>Digitalis Glycosides - therapeutic use</topic><topic>Disability Evaluation</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart Rate</topic><topic>Humans</topic><topic>Hyperlipidemias - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Placebos</topic><topic>Recurrence</topic><topic>Risk</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahlmark, G</creatorcontrib><creatorcontrib>Saetre, H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahlmark, G</au><au>Saetre, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term treatment with beta-blockers after myocardial infarction</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1976-06-15</date><risdate>1976</risdate><volume>10</volume><issue>2</issue><spage>77</spage><pages>77-</pages><issn>0031-6970</issn><abstract>162 patients discharged from hospital after mycardial infarction were randomly allocated to two groups, one received alprenolol 400 mg daily and the other served as the control. The period of follow-up was two years and all other treatment given was standardized. The two groups did not differ with respect to risk factors for myocardial infarction, the course of the acute infarct or treatment during follow-up. After two years one patient in the group treated with alprenolol had died suddenly as compared to nine in the control group. During the same period four fresh infarcts had occurred in the alprenolol group compared to 15 in the control group. Both these differences were statistically significant. Only four patients were obliged to discontinue beta-blocker treatment because of suspected side-effects. Long-term post-infarction treatment with beta-blockers appears to be an effective form of secondary therapy without serious side-effects.</abstract><cop>Germany</cop><pmid>134897</pmid><doi>10.1007/BF00609463</doi></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 1976-06, Vol.10 (2), p.77
issn 0031-6970
language eng
recordid cdi_pubmed_primary_134897
source MEDLINE; SpringerNature Journals
subjects Adult
Aged
Alprenolol - administration & dosage
Alprenolol - adverse effects
Alprenolol - therapeutic use
Angina Pectoris - epidemiology
Arrhythmias, Cardiac - epidemiology
Blood Pressure
Cardiomegaly
Clinical Trials as Topic
Digitalis Glycosides - therapeutic use
Disability Evaluation
Female
Follow-Up Studies
Heart Rate
Humans
Hyperlipidemias - epidemiology
Male
Middle Aged
Myocardial Infarction - drug therapy
Placebos
Recurrence
Risk
title Long-term treatment with beta-blockers after myocardial infarction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A12%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20treatment%20with%20beta-blockers%20after%20myocardial%20infarction&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Ahlmark,%20G&rft.date=1976-06-15&rft.volume=10&rft.issue=2&rft.spage=77&rft.pages=77-&rft.issn=0031-6970&rft_id=info:doi/10.1007/BF00609463&rft_dat=%3Cpubmed%3E134897%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/134897&rfr_iscdi=true